Antiviral therapy for enteroviruses and rhinoviruses

Antiviral Chemistry and Chemotherapy

Volumn 11, Issue 4, 2000, Pages 261-271

  Rotbart, Harley A ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Antiviral therapy; Enteroviruses; Interferon; Pleconaril; Protease inhibitors; Rhinoviruses

Indexed keywords

5 [5 [2,6 DICHLORO 4 (4,5 DIHYDRO 2 OXAZOLYL)PHENOXY]PENTYL] 3 METHYLISOXAZOLE; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CAPSID PROTEIN; DISOXARIL; ENVIROXIME; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERFERON; PLECONARIL; PROTEINASE INHIBITOR;

ANTIVIRAL ACTIVITY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; COXSACKIE VIRUS; DRUG EFFICACY; DRUG SAFETY; DRUG TOXICITY; ECHO VIRUS; ENTEROVIRUS; ENTEROVIRUS INFECTION; FLUSHING; HEPATITIS A VIRUS; HUMAN; NONHUMAN; NOSE IRRITATION; PICORNAVIRUS INFECTION; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; RASH; REVIEW; RHINOVIRUS; SIDE EFFECT; ULCER;

EID: 0033861007     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020001100402     Document Type: Review

References (121)

1. Abdel-Rahman SM & Kearns GL (1999) Single oral dose escalation pharmacokinetics of pleconaril capsules in adults. Journal of Clinical Pharmacology 39:613-618.
2. Abzug MJ, Levin MJ & Rotbart HA (1993) Profile of enterovirus disease in the first two weeks of life. Pediatric Infectious Disease Journal 12:820-824.
3. Al-Nakib W, Higgins PG, Barrow GI, Tyrrell DAJ, Andries K, Bussche, GV, Tayior N & Janssen PAJ (1989) Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837). Antimicrobial Agents and Chemotherapy 33:522-525.
4. Arruda E, Pitkaranta A, Witek TJ, Doyle CA & Hayden FG (1997) Frequency and natural history of rhinovirus infections in adults during autumn. Journal of Clinical Microbiology 35:2864-2868.
5. Barrow GI, Higgins PG, Tyrrell DAJ & Andries K (1990) An appraisal of the efficacy of the antiviral R 61837 in rhinovirus infections in human volunteers. Antiviral Chemistry and Chemotherapy 5:278-283.
6. Bergelson JM, Chan M, Solomon KR, St John NF, Lin H & Finberg RW (1994) Decay-accelerating factor (CD55), a glycosylphosphatidylinoitol-anchored complement regulatory protein, I a receptor for several echoviruses. Proceedings of the National Academy of Sciences, USA 91:6245-6248.
7. Bergelson JA, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivias A, Hong JS, Horwitz MS, Crowell RL & Finberg RW (1997) Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320-1323.
8. Black S (1983) Treatment of overwhelming neonatal ECHO 5 virus infection with intravenous gamma globulin (abstract no. 314). In: Program and abstracts of the 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Las Vegas). Washington, DC: American Society for Microbiology, p. 140.
9. Bultman BD, Eggers HJ, Gaile J & Haferkamp O (1983) Age dependence of paralysis induced by echovirus type 9 in infant mice. Journal of Infectious Disease 147:999-1005.
10. Buontempo P, Cox S, Wright-Minogue J, DeMartino Skelton A, Albin R, Rozhon E, Girijavallabhan V & O'Connell JF (1997) SCH 48973: A potent, broad spectrum antienterovirus compound. Antimicrobial Agents and Chemotherapy 41:1220-1225.
11. Capobianchi MR, Matteucci D, Glovannetti A, Soldaini E, Bendineiii M, Stanton JG & Dianzani F (1991) Role of interferon in lethality and lymphoid atrophy induced by coxsackievirus S3 infection mice. Virology and Immunology 5:103-110.
12. Centers for Disease Control and Prevention (1996) Progress toward global eradication of poliomyelitis. Morbidity and Mortality Weekly Report 45:565-8.
13. Centers for Disease Control and Prevention (1997) Progress toward poliomyelitis eradication - Africa, 1996. Morbidity and Mortality Weekly Report 46:321-325.
14. Chebath J & Benech P (1987) Constiruitive expression of (2′-5′) oligo A synthetase confers resistance to picornavirus infection. Nature 330:587-588.
15. Cherry JD (1998) Enteroviruses: Coxsackieviruses, echoviruses, and polioviruses. In Textbook of Pediatric Infectious Diseases 4th Edition. Edited by Feigin RD and Cherry JD. Philadephia: WB Saunders, pp. 1787-1838
16. Chidekel AS, Bazzy AR & Rosen CL (1994) Rhinovirus infection associated with severe lower respiratory tract illness and worsening lung disease in infants with bronchopulmonary dysplasia. Pediatric Pulm 18:261-263.
17. Chonmaitree T & Baron S (1991) Bacteria and viruses induce production of Interferon in the cerebrospinal fluid of children with acute meningitis: a study of 57 cases and review. Reviews of Infectious Diseases 13:1061-1065.
18. Collinson J, Nicholson KG, Cancio E, Ashman J, Ireland DC, Hammersley V, Kent J & O'Callaghan C (1996) Effects of upper respiratory tract infections in patients with cystic fibrosis. Thorax 51:1115-1122.
19. Cox S, Bunotempo P, Wright-Minogue J, DeMartino, Skelton A, Ferrari E, Schwartz J, Rozhon E, Linn C, Girijavallabhan V & O'Connell JF (1996) Antipicornavirus activity of SCH 47802 and Analogues: in vitro and in vivo studies. Antiviral Research 32:71-79.
20. Dagan R & Menegus MA (1986) A combination of four cell types for rapid detection of enteroviruses in clinical specimens. Journal of Medical Virology 19:219-228.
21. Dalakas MC, Sever JL, Madden DL, Papadopoulos NM, Shedarchi IC, Albrecht P & A Krezlewicz (1984) Late postpoliomyelitis muscular atrophy: clinical, virologic, and immunologic studies. Reviews of Infectious Diseases 6:S562-S567.
22. Dalakas MC (1995) Enteroviruses and human neuromuscular diseases. In Human enteroviruses infections Edited by Rotbart HA. Washington DC: ASM Press, pp. 387-398.
23. DeLong DC, Nelson JD, Wu E, Warren B, Wikel J, Templeton RJ & Dinner A (1978a) Virus inhibition studies with AR -36 III. Relative activity of syn and anti isomers. Abstract 34. In Program and abstracts of the 18th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington DC.
24. DeLong DC, Nelson JD, Wu CYE, Warren B, Wikel J, Chamberlin J, Montgomery D & Paget CJ (1978b) Virus inhibition studies with AR-336. 1. Tissue culture activity. Abstract S-128, p234. In Abstracts of the 78th Annual Meeting of the American Society for Microbiology. American Society for Microbiology, Washington DC.
25. Dick EC (1968) Experimental infections of chimpanzees with human rhinovirus types 14, and 43. Proceedings of the Society for Experimental Biology Medicine 127:1079-1081.
26. Douglas RM, Moore BW, Miles HB, Davies LM, Graham N, Ryan P, Worswick D & Albricht J (1986) Prophylactic efficacy of intranasal alpha A2-interteron against rhinovirus infections in the family setting. New England Journal of Medicine 314:65-70.
27. Enders JF, Weller TH & Robbins FC (1949) Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 109:M-87.
28. Fox MP, McKinlay MA, Diana GD & Dutko FJ (1991) Binding affinities of structurally related human rhinovirus capsid-binding compounds are related to their activities against human rhinovirus type 14. Antimicrobial Agents and Chemotherapy 35:1040-1047.
29. Geniteau-Legendre M, Forestier F, Quero AM & German A (1987) Role of interferon, antibodies and macrophages in the protective effect of Corynebacterium parvum on encephalomyocarditis virus-induced disease in mice. Antiviral Research 7:161-167.
30. Ghosh S, Champlin R, Couch R, Englund J, Raad I, Malik S, Luna M & Whimbey E (1999) Rhinovirus infections in myelosuppressed adult blood and marrow transplant recipients. Clinical Infectious Diseases 29:528-532.
31. Gonzales R, Steiner JF & Sande MA (1998) Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. Journal of the American Medical Association 278:901-904.
32. Greenberg SB, Harmon MW, Couch RB, Johnson PE, Wilson SZ, Dacso CC, Bloom K & Quarles J (1982) Prophylactic effect of low doses of human leukocyte interferon against infection with rhinovirus. Journal of Infectious Disease 145:542-546.
33. Gwaltney JM Jr. (1989) Viral infection of humans. In Rhinoviruses. Edited by Evans, pp. 593. New York: Plenum Medical Book Co.
34. Gwaltney JM Jr, Phillips CD, Miller RD & Riker DK (1994) Computed tomographic study of the common cold. New England Journal of Medicine 330:25-30.
35. Hayden FG & Gwaltney JM Jr (1982) Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection. Antimicrobial Agents and Chemotherapy 21:892-897.
36. Hayden F & Gwaltney JM (1983) Intranasal interferon alpha2 for prevention of rhinovirus infection and illness, Journal of Infectious Disease 148:543-550.
37. Hayden F & Gwaltney JM (1984) Intranasal interferon-a2 treatment of experimental rhinovirus colds. Journal of Infectious Disease 150:174-180.
38. Hayden F, Albrecht JK, Kaiser DL & Gwaltney JM (1986) Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. New England Journal of Medicine 314:71-75.
39. Hayden FG, Andries A & Janssen PAJ (1992) Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrobial Agents and Chemotherapy 36:727-732.
40. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract LB-3; San Francisco, CA.
41. Heinz BA, Rueckert RR, Shepard DA, Dutko FJ, McKinlay MA, Fancher M, Rossmann MG, Badger J & Smith TJ (1989) Genetic and molecular analysis of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. Journal of Virology 63:2476-2485.
42. Heinz BA (1990) Escape mutant analysis of a drug-binding site can be used to map functions in the rhinovirus capsid. In Use of X-Ray Crystallography in the Design of Antiviral Agents. Edited by WG Laver and GA Air. San Diego, Calif: Academic Press Inc, pp. 173-186.
43. Heinz BA & Vance LM (1995) The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. Journal of Virology 69:4189-4197.
44. Hellen CUT & Wimmer E (1995) Enterovirus Genetics. In Human Enterovirus Infections. Edited by Rotbart HA. Washington DC: ASM Press, pp. 25-72.
45. Ho M, Chen E-R, Hsu K-H, Twu SJ, Chen KT, Tsai SF, Wang JR, & Shih SR (1999) An epidemic of enterovirus 71 infection in Taiwan. New England Journal of Medicine 341:929-935.
46. Hogle JM, Chow M & Filman DJ (1985) Three-dimensional structure of poliovirus at 2.9A resolution. Science 229:1358-1365.
47. Ichimura H, Shimase K, Tamura I, Kaneto E, Kurimura O, Aramftsu Y & Kurimura T (1985) Neutralizing antibody and interferon-alpha in cerebrospinal fluids and sera of acute aseptic meningitis. Journal of Medical Virology 15:231-237.
48. Jantausch BA, Luban NLC, Duffy L & Rodriquez WJ (1995) Maternal plasma transfusion in the treatment of disseminated neonatal echovirus 1 1 infection. Pediatric Infectious Disease Journal 14:154-155.
49. Jenista JA, Powell KR & Menegus MA (1984) Epidemiology of neonatal enterovirus infection. Journal of Pediatrics 104:685-690.
50. Johnson KL & Sarnow P (1995) Viral RNA synthesis. In Human Enterovirus Infections. Edited by Rotbart HA. Washington DC: ASM Press, pp. 95-112.
51. Johnston JM & Overall JC Jr (1989) Intravenous immunoglobulin in disseminated neonatal echovirus 11 infection. Pediatric Infectious Disease Journal 8:254-256.
52. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F & Josephs L (1995) Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. British Medical Journal 310:1225-1229.
53. Jubeit B, Wilson AK, Ronka SI, Guidinger PI & McKinlay MA (1989) Clearance of a persistent human enterovirus infection of the mouse central nervous system by the antiviral agent disoxaril. Journal of Infectious Disease 159:866-871.
54. Kandolf R, Canu A & Hofschneider PH (1985) Coxsackie B3 virus can replicate in cultured human foetal heart cells and is inhibited by interferon. Journal of Molecular and Cellular Cardiology 17:167-181.
55. th Annual Infectious Diseases Society of America Meeting, Denver, CO. Abstract 750.
56. Kearns GL, Abdel-Rahman SM, James LP, Blowey DL, Marshall JD, Wells TG & Jacob RF (1999) Single-dose pharmacokinetics of a pleconaril oral solution in children and adolescents. Antimicrobial Agents and Chemotherapy 43:634-638.
57. Kishimoto C, Crumpacker CS & Abelmann WH (1988) Prevention of murine Coxsackie B3 viral myocarditis and associated lymphoid organ atrophy with recombinant human leucocyte interferon alpha A/D. Cardiovascular Research 22:732-738.
58. Klingel K, Stephan S, Suater M, Zell R, McManus BM, Bultman BD & Kandolf R (1996). Pathogenesis of murine enterovirus myocarditis: virus dissemination and immune cell targets. Journal of Virology 70:8888-8895.
59. Landry ML (1999) Rhinoviruses. In Manual of Clinical Microbiology. Edited by Murray PR, Baron EJ, Pfaller MA et al. Seventh Edition. Washington, DC: ASM Press, pp. 983-989.
60. Langford MP, Barber JC, Sklar VE, Clark III, SW, Patriarca PA, Onarato IM, Yin-Murphy M & Stanton GJ (1985) Virus-specific, early appearing neutralizing activity and interferon production in patients with acute hemorrhagic conjunctivitis. Current Eye Research 4:233-239.
61. Langford MP, Kadi RM, Ganley JP & Yin-Murphy M (1988) Inhibition of epidemic isolates of Coxsackie virus type A24 by recombinant and natural interferon alpha and interferon beta. Intervirology 29:320-327.
62. Last-Barney KL, Madin SD, Pal K, Cahill-Feehan C, McNally EJ, Jeanfavre DD & Meduzzii VJ (1993) Method for detection of picornavirus capsid binders with soluble intracellular adhesion molecule 1. Antimicrobial Agents and Chemotherapy 37:1693-1695.
63. Lopez-Guerrero JA, Pimentel-Muinos FX, Fresno M & Alonso MA (1990) Role of soluble cytokines on the restricted replication of poliovirus in the monocylic U937 cell line. Virus Research 16:225-230.
64. Makela MJ, Puhakka T, Ruuskanen O, Leinonen M, Saikku P, Kimpimaki M, Blomqvist S, Hyypia T & Arstila P (1998) Viruses and bacteria in the etiology of the common cold. Journal of Clinical Microbiology 36:539-542.
65. Martino TA, Liu P, Petric M & Sole MJ (1995) Enteroviral myocarditis and dilated cardiomyopathy: a review of clinical and experimental studies. In Human Enterovirus Infections. Edited by Rotbart HA. Washington DC: ASM Press, pp. 291-351.
66. McKinlay MA, Frank JA & Steinberg BA (1986) Use of WIN 51711 to prevent echovirus type 9-induced paralysis in suckling mice. Journal of Infectious Disease 154:676-681.
67. McKinlay MA & Steinberg BA (1986) Oral efficacy of WIN 51711 in mice infected with human poliovirus. Antimicrobial Agents and Chemotherapy 29:30-32.
68. McKinney RE, Katz SL & Wilfert CM (1987) Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Reviews of Infectious Diseases 9:334-56.
69. Melnick JL & Godman GC (1951) Pathogenesis of coxsackievirus infection. Multiplication of virus and evolution of muscle lesions in mice. Journal of Experimental Medicine 93:247-266.
70. Merigan T, Reed S, Hall T & Tyrrell D (1973) Inhibition of respiratory virus infection by locally applied interferon. Lancet i:536-567.
71. Miller FD, Monto AS, DeLong DC, Exelby A, Bryan ER & Srivastava S (1985) Controlled trail of enviroxime against natural rhinovirus infections in a community. Antimicrobial Agents and Chemotherapy 27:102-106.
72. Miller MJ (1997) Viral taxonomy. Clinical Infectious Diseases 25:18-19.
73. Modlin JF, Polk BF, Horton P, Etkind P, Crane E & Spiliotes A (1981) Perinatal echovirus infection; risk of transmission during a community outbreak. New England Journal of Medicine 305:368-371.
74. Modlin JF, Dagan R, Berlin LE, Virshup DM, Yolken RH & Menegus M (1991) Focal encephalitis with enterovirus infections. Pediatrics 88:841-845.
75. Monto AS, Schwanz S & Albrecht JK (1989). Ineffectiveness of postexposure prophylaxis of rhinovirus infection with low-dose intranasal alpha 2b interferon in families. Antimicrobial Agents and Chemotherapy 33:387-390.
76. Muir P, Nicholson F, Spencer GT, Ajetunmobi JF, Starkey WG, Khan M, Archard LC, Cairns NJ, Anderson VE, Leigh PN, Howard RS & Banatvala JE (1996) Enterovirus infection of the central nervous system of humans: lack of association with chronic neurological disease. Journal of General Virology 77:1469-1476.
77. Nicholson KG, Kent J & Ireland DC (1993) Respiratory viruses and exacerbations of asthma in adults. British Medical Journal 307:982-986.
78. Nicholson KG, Kent J, Hammersley V & Gancio E (1996) Risk factors for lower respiratory complications of rhinovirus infections in elderly people living in the community: prospective cohort study. British Medical Journal 313:1119-1123.
79. Ninomiya Y, Shimma N & Ishksuka H (1990) Comparative studies on the mode of action of rhinovirus capsid binding agents, chalcone amides. Antiviral Research 15:61-74.
80. Nyquist A-C, Gonzales R, Steiner JF & Sande MA (1998) Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis. Journal of the American Medical Association 279:875-877.
81. Okada I, Matsumori A, Matoba Y, Tominaga M, Yamada T & Kowai C (1992) Combination treatment with ribavirin and interferon for coxsackievirus B3 replication. Journal of Laboratory and Clinical Medicine 120:569-573.
82. Otto MJ, Fox MP, Fancher MJ, Huhrt MF, Diana GD & McKinlay MA (1985) In vitro activity of WIN 5171 1, a new broad-spectrum antipicornavirus drug. Antimicrobial Agents and Chemotherapy 27:883-886.
83. Patick AK, Ford C, Binford S, et al. (1997) Evaluation of the antiviral activity and cytotoxicfty of peptice inhibitors of human rhinovirus 3C protease, a novel target for antiviral intervention. Abstracts of the 10th International Conference on Antiviral Research, Atlanta, Ga., USA pA75.
84. Pevear DC, Fancher MJ, Felock PJ, Rossmann MG, Miller MS, Diana GD, Treasurywala AM, McKinlay MA & Dutko FJ (1989) Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa Cell receptors. Journal of Virology 63:2002-2007.
85. th Annual Clinical Virology Symposium; Clearwater, Fla., USA.
86. Pevear DC, Tull TM, Seipel ME & Groarke JM (1999) Activity of pleconaril against enteroviruses. Antimicrobial Agents and Chemotherapy 43:2109-2115.
87. Philipotts RJ, DeLong DC, Wallace J, Jones RW, Reed SE & Tyrrell DAJ (1981) The activity of enviroxime against rhinovirus infection in man. Lancet ii:1342-1344.
88. Philipotts RJ, Wallace J, Tyrrell DAJ & Tagart VB (1983) Therapeutic activity of onviroxime against rhinovirus infection in volunteers. Antimicrobial Agents and Chemotherapy 23:671-675.
89. Pinto CA & Haff RF (1969) Experimental infection of gibbons with rhinovirus. Nature 224:1310-1311.
90. Pitkaranta A, Linnavouri K & Houi T (1991) Virus-induced interferon production in human leukocytes: a low responder to one virus can be a high responder to another virus. Journal of Interferon Research 11:17-23.
91. Pitkaranta A, Virolainen A, Jero J, Arruda E & Hayden FG (1998) Detection of rhino-virus, respiratory syncytial virus, and coronavirus infections in acute otitis media by reverse transcriptase polymerase chain reaction. Pediatrics 102:291-295.
92. Racaniello VR (1995) Early events in infection:receptor binding and cell entry. In Human Enterovirus Infections. Edited by Rotbart HA. Washington DC: ASM Press, pp. 73-93.
93. Rewers M & Atkinson M (1995) The possible role of enteroviruses in diabetes mellitus. In Human Enterovirus Infections. Edited by Rotbart HA. Washington DC: ASM Press, pp. 353-385.
94. Rombaut B, Vrijsen R & Boeye A (1985) Comparison of arildone and 3-methylquercetin as stabilizers of poliovirus. Antiviral Research 1(Suppl.):67-73.
95. Rombaut B, Andries K & Boeye A (1991) A comparison of WIN 51711 and R 78206 as stabilizers of poliovirus virions and procapsids. Journal of General Virology 72:2153-2157.
96. Rotbart HA, Sawyer MH, Fast S, Lewinski C, Murphy N, Keyser EF, Spadoro J, Kao SY & Loeffelhoiz M (1994) Diagnosis of enterovirus meningitis using the polymerase chain reaction with a calorimetric microwell detection assay. Journal of Clinical Microbiology 32:2590-2592.
97. Rotbart HA (1997) Viral meningitis and the aseptic meningitis syndrome. In Infections of the Central Nervous System, 2nd edition. Edited by Scheld WM, Whitley RJ and Durack DT. Philadelphia: Lippincott-Raven, pp. 23-46
98. Rotbart HA, Brennan PJ, Fife KH, Romero JR, Griffin JA, McKinlay MA & Hayden FG (1998) Enterovirus meningitis in adults. Clinical Infectious Diseases 27:896-898.
99. Rotbart HA & Webster ADB (1999) Treatment of potentially life-threatening enterovirus infections with pleconaril. Submitted for publication.
100. Rueckert RR (1990) Picornaviruses and their replication. In Virology. Edited by BN Fields and DM Knipe. New York: Raven Press, pp. 507-548.
101. Samo TC, Greenberg SB, Couch RB, Quarles J, Johnson PE, Hook S & Harmon MW (1983) Efficacy and tolerance of intranasal applied recombinant leukocyte A interferon in normal volunteers. Journal of Infectious Diseases 148:535-542.
102. Sasaki O, Karaki T & Imanishi J (1986) Protective effect of interferon on infections with hand, foot and mouth disease virus in newborn mice. Journal of Infectious Diseases 153:498-502.
103. Sawyer MH, Saez-Llorenz X, Aviles CL, et al. (1999) Oral pleconaril reduces the duration and severity of enteroviral meningitis in children. Proceedings of the 1999 APS/SPR meetings, San Francisco, Calif.
104. Schiff GM, Sherwood JR, Young EC & Mason LJ (1992) Prophylactic efficacy of WIN 54954 in prevention of experimental human coxsackievirus A21 infection and illness. Antiviral Research supplement 17:92.
105. th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, La. Abstract H-43.
106. Schmidt HJ & Fink RJ (1991) Rhinovirus as a lower respiratory pathogen in infants. Pediatric Infectious Disease Journal 10:700-702.
107. th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Calif. Abstract 1904,
108. Strikas RA, Anderson LJ & Parker RA (1986) Temporal and geographic patterns of isolates of nonpolio enterovirus in the United States, 1970-1983. Journal of Infectious Diseases 153:346-351.
109. Tebbe MJ, Spitzer WA & Tang J (1997) Oral bioavailability screening of the antirhinoviral vinyl acetylene benzimidazoles. Abstracts of the 10th International Conference on Antiviral Research, Atlanta, Ga., USA; pA89.
110. Tebbe MJ, Spitzer WA, Victor S, et al. (1997) Antirhinoviral vinyl acetylene benzimidazoles. Abstracts of the 10th International Conference on Antiviral Research, Atlanta, Ga., USA; pA75.
111. Turner RB, Dutko FJ, Goldstein NH, Lockwood G & Hayden FG (1993) Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection. Antimicrobial Agents and Chermotherapy 37:297-300.
112. Turner RB (1998) The common cold. Pediatric Annals 27:790-795.
113. Wadia NH, Wadia PN, Katrak SM & Misra VP (1983) A study of the neurological disorder associated with acute hemorrhagic conjunctivitis due to enterovirus 70. Journal of Neurology Neurosurgery and Psychology 46:599-610.
114. Webster ADB, Rotbart HA, Warner T, Rudge P & Hyman N (1993) Diagnosis of enterovirus brain disease in hypogammaglobulinemic patients by polymerase chain reaction. Clinical Infectious Disease 17:657-661.
115. Whitley RJ, Cobbs CG, Alford CA, Soong Sj, Hirsch MS, Connor JD, Corey L, Hanley DF, Levin M & Powell DA (1989) Diseases that mimic herpes simplex encephalitis. Journal of the American Medical Association 262:234-239.
116. Wikel JH, Paget CJ, DeLong DC, Nelson JD, Wu CYE, Paschal JW, Dinner A, Templeton RJ, Chaney MO, Jones ND & Chamberlin JW (1980) Synthesis of syn and anti isomers of 6-(hydroxyimino)phenametha-I-[(I-methylethyl)sulfonyl]-1 H-benz-imidazol-2-amine. Inhibitors or rhinovirus multiplication. Journal of Molecular Chemistry 23:368-372.
117. Wong SN, Tam AY, Ng TH, Ng WF, Tong CY & Tang TS (1989) Fatal Coxsackie B1 virus infection in neonates. Pediatric Infectious Disease Journal 8:638-641.
118. Woods MG, Diana GD, Rogge MC, Otto MJ, Dutko FJ & McKinlay MA (1989) In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrobial Agents and Chemotherapy 33:2069-2074.
119. Yasin SR, Al-Nakib W & Tyrell DAJ (1990). Pathogenecity for humans of human rhinovirus type 2 mutants resistant to or dependent on chalcone Ro OM410. Antimicrobial Agents and Chemotherapy 34:963-966.
120. Zhang A, Nanni RG, Arnold GF, Oren DA, Li T, Jacobo-Molkina A, William RL, Kamer G, Rubenstein DA, Li Y, Rozhon E, Cox S, Bumotempo P, O'Connell J, Schwartz J, Miller G, Nash C, Bauer B, Versace R, Ganguly A, Girijavallabhan V & Arnold E (1991) Structure of a complex of human rhinovirus 14 with a water soluble antiviral compound SCH 38057. Journal of Molecular Siology 230:857-867.
121. Zhang A, Nanni RG, Oren DA, Rozhon EJ & Arnold E (1992) Three-dimensional structure-activity relationships for antiviral agents that interact with picornavirus capsids. Seminars in Virology 3:453-471.